Withdrawal of Inhaled Corticosteroids from Patients with COPD; Effect on Exacerbation Frequency and Lung Function: A Systematic Review

References

• Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–459. doi:10.1146/annurev.pathol.4.110807.092145
   PubMed Web of Science ®Google Scholar
• Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. Int J Chron Obstruct Pulmon Dis. 2019;14:1267–1280. doi:10.2147/COPD.S207775
   PubMed Web of Science ®Google Scholar
• Nielsen AO, Hilberg O, Jensen JUS, et al. Withdrawal of inhaled corticosteroids in patients with COPD - A prospective observational study. Int J Chron Obstruct Pulmon Dis. 2021;16:807–815. doi:10.2147/COPD.S294217
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020;166:105938. doi:10.1016/j.rmed.2020.105938
   PubMed Web of Science ®Google Scholar
• 2023 GOLD Report. Global initiative for chronic obstructive lung disease - GOLD. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed April 26, 2023.
   Google Scholar
• Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023
   PubMed Web of Science ®Google Scholar
• Patel S, Dickinson S, Morris K, Ashdown HF, Chalmers JD. A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients. NPJ Prim Care Respir Med. 2022;32(1):25. doi:10.1038/s41533-022-00288-6
   PubMed Web of Science ®Google Scholar
• Yawn BP, Suissa S, Rossi A. Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. NPJ Prim Care Respir Med. 2016;26:16068. doi:10.1038/npjpcrm.2016.68
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European respiratory society guideline. Eur Respir J. 2020;55(6):2000351. doi:10.1183/13993003.00351-2020
   PubMed Web of Science ®Google Scholar
• Harries TH, Rowland V, Corrigan CJ, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3. doi:10.1186/s12931-019-1268-7
   PubMed Web of Science ®Google Scholar
• Harries TH, Gilworth G, Corrigan CJ, et al. Withdrawal of inhaled corticosteroids from patients with COPD with mild or moderate airflow limitation in primary care: a feasibility randomised trial. BMJ Open Respir Res. 2022;9(1):e001311. doi:10.1136/bmjresp-2022-001311
   PubMed Web of Science ®Google Scholar
• Cataldo D, Derom E, Liistro G, et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int J Chron Obstruct Pulmon Dis. 2018;13:2089–2099. doi:10.2147/COPD.S164259
   PubMed Web of Science ®Google Scholar
• Nadeem NJ, Taylor SJC, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD--A systematic review and comment on trial methodology. Respir Res. 2011;12(1):107. doi:10.1186/1465-9921-12-107
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Braido F, et al. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulm Pharmacol Ther. 2017;45:148–158. doi:10.1016/j.pupt.2017.06.002
   PubMed Web of Science ®Google Scholar
• Neches García V, Vallejo-Aparicio LA, Ismaila AS, et al. Clinical and economic impact of long-term inhaled corticosteroid withdrawal in patients with chronic obstructive pulmonary disease treated with triple therapy in Spain. Int J Chron Obstruct Pulmon Dis. 2022;17:2161–2174. doi:10.2147/COPD.S367708
   PubMed Web of Science ®Google Scholar
• Whittaker HR, Wing K, Douglas I, Kiddle SJ, Quint JK. Inhaled corticosteroid withdrawal and change in lung function in primary care patients with chronic obstructive pulmonary disease in England. Ann Am Thorac Soc. 2022;19(11):1834–1841. doi:10.1513/AnnalsATS.202111-1238OC
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
   Google Scholar
• Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A systematic approach to searching: an efficient and complete method to develop literature searches. J Med Libr Assoc JMLA. 2018;106(4):531–541. doi:10.5195/jmla.2018.283
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. 2012. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed June 4, 2024.
   Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394. doi:10.1016/j.jclinepi.2010.04.026
   PubMed Web of Science ®Google Scholar
• O’brien A, Russo-Magno P, Karki A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med. 2001;164(3):365–371. doi:10.1164/ajrccm.164.3.2002052
   PubMed Web of Science ®Google Scholar
• Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8(1):93. doi:10.1186/1465-9921-8-93
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166(10):1358–1363. doi:10.1164/rccm.200206-512OC
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC
   PubMed Web of Science ®Google Scholar
• Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirol Carlton Vic. 2018;23(12):1152–1159. doi:10.1111/resp.13374
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa1407154
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. doi:10.1183/09031936.00126814
   PubMed Web of Science ®Google Scholar
• Wouters EFM, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60(6):480–487. doi:10.1136/thx.2004.034280
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Gaga M, Aalamian-Mattheis M, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017;18(1):140. doi:10.1186/s12931-017-0622-x
   PubMedGoogle Scholar
• Rossi A, Guerriero M, Corrado A; OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15(1):77. doi:10.1186/1465-9921-15-77
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Worth H, Buhl R, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis. 2017;12:487–494. doi:10.2147/COPD.S125616
   PubMed Web of Science ®Google Scholar
• Magnussen H, Lucas S, Lapperre T, et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respir Res. 2021;22(1):25. doi:10.1186/s12931-021-01615-0
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Single-inhaler triple versus dual bronchodilator therapy in COPD: real-world comparative effectiveness and safety. Int J Chron Obstruct Pulmon Dis. 2022;17:1975–1986. doi:10.2147/COPD.S378486
   PubMed Web of Science ®Google Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi:10.1164/rccm.201310-1863PP
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-4
   PubMed Web of Science ®Google Scholar
• Schroeder MN, Sens HM, Shah SK. De-prescribing inhaled corticosteroids in chronic obstructive pulmonary disease: a narrative review. J Pharm Pract. 2022;8971900221144127. doi:10.1177/08971900221144127
   Web of Science ®Google Scholar